Fintel reports that on January 6, 2026, Citigroup upgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Buy. Analyst Price Forecast Suggests 11.58% Upside As of December 22, 2025, the ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural ...

The U.S. had a Christmas gift for each of the men in South Viet Nam’s 1st Regiment of the 1st Division, based just south of the Demilitarized Zone. It was the lightweight, fast-firing M-16 rifle, ...

Arvinas (NASDAQ:ARVN) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Quanterix Corporation ("Quanterix" or the "Company") , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of ...

He was just a boy when his dad was killed, leaving Bill Kelley much to learn about the man his dad was through the many letters and writings he left behind and from the people who knew and served with ...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a ...

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product ...

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.